Exabis Library
Welcome to the e-CCO Library!
DOP42: Impact of discontinuing thiopurines at anti-TNF initiation in Inflammatory Bowel Disease: A nationwide Danish cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: Results of the OCTAVE Open study for tofacitinib delayed responders
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP43: The risk of extra-intestinal cancer in Inflammatory Bowel Disease (IBD): A systematic review and meta-analysis of population-based cohort studies
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP44: Cancer risk in a high-incidence Inflammatory Bowel Disease population – a Faroese IBD cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multicentric study from GETECCU
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP45: Increased prevalence but not incidence of myocardial infarction and stroke in patients with Inflammatory Bowel Diseases in Quebec in 1996-2015
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP46: Extended induction treatment with mirikizumab in patients with moderately-to-severely active ulcerative colitis: results from a phase 2 trial
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the phase 3 UNIFI maintenance study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP47: The changing pattern of Inflammatory Bowel Disease incidence in Northern France: A continuing increase in the young women (1988-2014)
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof of concept study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP48: Gene expression landscape of epithelial monolayer in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP49: Quantitative proteomics analysis of macrophages from Crohn’s Disease patients and infected with adherent-invasive Escherichia coli
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP50: The landscape of somatic mutations in non-neoplastic IBD-affected colon
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel Diseases
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP52: Reduction in inflammatory biomarkers in a phase 2 study of mirikizumab in patients with moderately-to-severely active ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP52: The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s Disease or Ulcerative Colitis reflects the respective disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP53: Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, pan-JAK Inhibitor TD-1473 in Moderately-to-Severely Active Ulcerative Colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1